Treatment of subjects with refractory periodontal disease.
The aim of the present study was to evaluate the effect of non-surgical periodontal therapy with the adjunct of a selected antibiotic in subjects diagnosed with refractory periodontal disease. 21 subjects were selected for the study; all had a history of periodontal surgery, tetracycline therapy, and regular maintenance by a periodontist. When disease activity was detected, a bacterial sample was taken and a whole plaque susceptibility test was performed. Before the outcome of the susceptibility test the subjects were assigned to either antibiotic or placebo therapy. All subjects received scaling and rootplaning prior to antibiotic or placebo therapy. Based on the susceptibility test, subjects in the antibiotic group were treated either with Augmentin or clindamycin. The results demonstrated that in subjects with refractory periodontal disease there was no significant difference (N.S.) in the proportion of sites losing attachment before and after treatment (11.3% and 12.4%, respectively) over a 2-year post therapy observation period. However, the proportion of sites showing gain of attachment increased from 0.9% before therapy to 5.1% (p = 0.029) following selective antibiotic therapy when combined with scaling and rootplaning. The remainder of sites showed no change between pre- and post-therapy monitoring periods. The progression of attachment loss in the active sites could not be completely stopped over the entire 2-year period. After 12-15 months following therapy, there was a tendency towards new loss of attachment and an increase of pocket depth. However, all 4 subjects treated with placebo drug demonstrated continuous deterioration and had to be retreated. Although the proportion of sites losing attachment decreased from 5.1% to 2.3% (N.S.), the proportion of sites gaining attachment also decreased from 2.0% to 1.0% (N.S.). The results suggest that scaling and rootplaning together with selected antibiotic therapy repeated every 12-15 months may be beneficial for these subjects although it may not completely stop progressive attachment loss.
Magnusson
I
I
Periodontal Disease Research Center, College of Dentistry, University of Florida, Gainesville 32610.
Low
S B
SB
McArthur
W P
WP
Marks
R G
RG
Walker
C B
CB
Maruniak
J
J
Taylor
M
M
Padgett
P
P
Jung
J
J
Clark
W B
WB
D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D001419:Bacteria / Q000302:isolation & purification; D016022:Case-Control Studies; D002969:Clavulanic Acids / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003774:Dental Plaque Index; D012534:Dental Scaling; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy; D010510:Periodontal Diseases / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy*; D010512:Periodontal Index; D010919:Placebos; D012008:Recurrence; D016745:Root Planing
D002969:Clavulanic Acids; D010919:Placebos; D002981:Clindamycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin